July 3, 2019

Update on the Journal and some key articles

The ICMx Editor-in-Chief tells us more about the journal’s most recent content

Launched in 2013, the journal is now in its sixth year of existence. The number of submissions is steadily growing, and in particular, the number of citations – totalling more than 600 during the last 18 months – has been on a steep upward slope.  Moreover, citations are reaching out far beyond the field of critical care.

Intensive Care Med Experimental also offers a platform for proceedings of critical care-related symposia, e.g. the INSPIRES (International Symposium on Acute Pulmonary Injury Research) conference.

We are actively “updating” papers published about a decade ago and, hence, the journal has launched a “ten years later update” series of review articles on “Gaseous Mediators”, which will cover not only the well-known molecules nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S), the noble gases helium (He) and argon (Ar), but also “new players”, such as methane (CH4) and hydrogen selenide (H2Se), some of them being “endogenously produced vital poisons” with large potential for intensive care medicine. These articles are going to be published in the last quarter of 2019.


Here is a selection of some of the most recent OPEN ACCESS articles:


Lauren Miller, Kai Singbartl, Zissis C. Chroneos, Victor Ruiz-Velasco, Charles H. Lang, Anthony Bonavia:

Resistin directly inhibits bacterial killing in neutrophils.

Intensive Care Medicine Experimental 2019 7:30



An in vitro study demonstrating that human resistin impairs the ability of neutrophils to kill bacteria, while it mostly did not affect the ability of macrophages or monocytes to kill bacterial organisms. Resistin blocked bactericidal activity through suppression of the oxidative burst in neutrophils.

Nicholas L. Jackson Chornenki, Robert Coke, Andrew C. Kwong, Dhruva J. Dwivedi, Michael K. Xu, Ellen McDonald, John C. Marshall, Alison E. Fox-Robichaud, Emmanuel Charbonney, Patricia C. Liaw:

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis.

Intensive Care Medicine Experimental 2019 7:29



A study in patients showing that the source and mechanism of release of cfDNA differ between trauma and sepsis patients. While in sepsis, cfDNA seems to be primarily released by activated neutrophils via the process of netosis, damaged cells are the major source of trauma.

Melissa Mahajan, David DiStefano, Joshua Satalin, Penny Andrews, Hassan al-Khalisy, Sarah Baker, Louis A. Gatto, Gary F. Nieman, Nader M. Habashi:

Time-controlled adaptive ventilation (TCAV) accelerates simulated mucus clearance via increased expiratory flow rate.

Intensive Care Medicine Experimental 2019 7:27



A study of the effects of time-controlled adaptive ventilation on mucus clearance using mechanically ventilated porcine lungs ex vivo. The protocol ventilation resulted in the greatest proximal movement of simulated mucus as compared to the ARDSnet protocol groups in this model.

Alice Blet, Benjamin Deniau, Christopher Geven, Malha Sadoune, Anaïs Caillard, Paul-Robert Kounde, Evelyne Polidano, Peter Pickkers, Jane-Lise Samuel, Alexandre Mebazaa:

Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats

Intensive Care Medicine Experimental 2019 7:25



An in vivo study using rats with sepsis induced by cecal-ligation-and-puncture. In these animals, adrecizumab, a non-neutralizing anti-adrenomedullin antibody, rapidly restored haemodynamics and attenuated myocardial oxidative stress, thus providing a complementary mechanistic support for the current proof-of-concept and dose-finding phase II trial (Adrenoss-2) in patients with septic shock and elevated concentrations of circulating adrenomedullin.

If you would you like your research to be featured in ICMx, check out our submission guidelines and submit your basic and experimental intensive care research here! ESICM members also receive a 40% discount on article processing fees!


Warm regards,

Peter Radermacher

Editor-In-Chief, Intensive Care Medicine Experimental


For more information about ICMx, click here.






Comment on this news